Introduction
============

Schizophrenia (SCZ) has a strong genetic component with a heritability of up to 80% ([@b1-mmr-21-04-1702],[@b2-mmr-21-04-1702]). Tardive dyskinesia (TD) is presented by repetitive and jerking movements in the face, neck and tongue and is considered to be a serious side effect associated with the use of specific antipsychotic medications that are used to treat SCZ and other mental illnesses. TD may demonstrate a comorbidity of 20--30% with SCZ ([@b3-mmr-21-04-1702],[@b4-mmr-21-04-1702]). Recent studies have reported that complex interactions of genetic, environmental and epigenetic factors play important roles in SCZ and TD ([@b4-mmr-21-04-1702]--[@b7-mmr-21-04-1702]). DNA methylation is an epigenetic mechanism that influences CG dinucleotides by adding a methyl group (CH~3~) to them. Previously, several studies have reported the association between DNA methylation and SCZ ([@b8-mmr-21-04-1702]--[@b12-mmr-21-04-1702]) and TD ([@b13-mmr-21-04-1702],[@b14-mmr-21-04-1702]).

Insulin resistance has reportedly been associated with atherosclerosis and type 2 diabetes ([@b15-mmr-21-04-1702]). The insulin receptor substrate 1 (*IRS1*) gene is located at 2q36.3 ([@b16-mmr-21-04-1702]--[@b18-mmr-21-04-1702]) and it may be involved in the regulation of critical metabolic and signaling and secretion pathways ([@b19-mmr-21-04-1702]--[@b22-mmr-21-04-1702]). A genome wide association study in a French sample showed that one single nucleotide polymorphism (SNP) rs2943641, within 500 kb upstream of the *IRS1* gene, was associated with type 2 diabetes, insulin resistance and hyperinsulinemia ([@b23-mmr-21-04-1702]). Furthermore, the *IRS1* gene DNA methylation was associated with high body mass index (BMI) scores and obesity ([@b24-mmr-21-04-1702],[@b25-mmr-21-04-1702]). However, there was no significant association between the methylation of the *IRS1* gene and type 2 diabetes ([@b26-mmr-21-04-1702]). Gunnell *et al* ([@b27-mmr-21-04-1702]) attempted to evaluate the SNP rs1801278 in the *IRS1* gene with SCZ but could not identify any significant association. Recently, *IRS1* gene methylation has been found to be associated with SCZ ([@b9-mmr-21-04-1702],[@b28-mmr-21-04-1702]). Pyrosequencing provides a quantitative analysis of DNA methylation levels ([@b29-mmr-21-04-1702]--[@b31-mmr-21-04-1702]) and has been employed to detect DNA methylation levels of the *IRS1* gene in type 2 diabetes ([@b26-mmr-21-04-1702]) and human islets of type 2 diabetes ([@b32-mmr-21-04-1702]).

A pilot study using methylated DNA immunoprecipitation coupled with next-generation sequencing (our unpublished data) revealed that the *IRS1* gene was hypomethylated in TD compared with SCZ groups. The present study aimed to quantify DNA methylation levels of the *IRS1* gene via pyrosequencing to examine the association of the *IRS1* gene DNA methylation levels with SCZ or TD. The general linear model (GLM) was used to examine the differences in the DNA methylation levels among diagnostic groups.

Materials and methods
=====================

### Participants

The present study recruited 10 SCZ patients with TD and 10 without TD (NTD) from the Beijing Huilongguan Hospital (China) between January 2016 and June 2017. SCZ was diagnosed using the Diagnostic and Statistical Manual of Mental Disorders version IV (DSM-IV) ([@b33-mmr-21-04-1702]) and TD was confirmed by two well-trained psychiatrists with extensive clinical experiences, based on the criteria of Schooler and Kane ([@b34-mmr-21-04-1702]). The 20 SCZ patients were administered with one of the following: Risperidone, paliperidone or olanzapine. The TD patients were typically between 18 and 40 years of age and demonstrated an abnormal involuntary movement scale (AIMS) score that was \>3 in at least one part or \>2 in two or more parts ([@b35-mmr-21-04-1702]). The same criteria were used for NTD patients with AIMS=0. The exclusion criteria included: Patients with severe physical or organic encephalopathy, drug or alcohol abuse history (except tobacco), pregnant or lactating women, patients administered with neurotrophic agents or free radical metabolism drugs within 12 weeks prior to participation, and other mental illnesses demonstrating a diagnosis of DSM-IV Axis I ([@b14-mmr-21-04-1702]). The severity of TD symptoms was assessed using AIMS, with an inter-rater correlation coefficient (ICC)\>0.80. The patients\' psychotic symptoms were evaluated using the positive and negative syndrome scale (PANSS) ([@b36-mmr-21-04-1702]), with an ICC\>0.85, which was maintained for the PANSS total score after the scale training. A total of 10 healthy controls (HCs) matched for age, sex and education were subsequently recruited from the local community. Ethical approval was received from the Ethics Review Board of Beijing Huilongguan Hospital, China, and written informed consent was obtained from all participants or their guardians.

### DNA extraction, bisulfite treatment and pyrosequencing

Fasting venous blood (5 ml) from a forearm vein was obtained from each participant at 7:00 a.m. the next morning after the day of clinical assessment. DNA was extracted from the above blood samples using a standard genomic DNA sample kit (Illumina, Inc.), according to the manufacturer\'s protocol. DNA concentration and purity were detected by NanoDrop spectrophotometer (NanoDrop Technologies, Thermo Fisher Scientific, Inc.) and the integrity was tested using 1% agarose gel electrophoresis ([@b14-mmr-21-04-1702]). Subsequently, 500 ng of each sample was treated with bisulfite, by employing the Epitect Bisulfite Kit (Qiagen GmbH), according to the manufacturer\'s protocol. Parts of the CpG islands in the promoter region within the *IRS1* gene were amplified with the help of PCR assays. DNA fragments were typically amplified using the PyroMark PCR kit (Qiagen GmbH), according to the manufacturer\'s protocol, from 2 µl bisulfite-treated genomic DNA. Sample preparation and pyrosequencing reactions were subsequently carried out using the PyroMark Q96 ID (Qiagen GmbH). The pyrosequencing assays were performed for all the study samples on both Pyro Mark Q24 MDx and PyroMarkQ96 ID, while using Pyro Mark Gold reagents (Qiagen GmbH). The Pyro Mark Assay Design software version 2.0 (Qiagen GmbH) was used to generate the primers for the *IRS1*, targeting four CpGs in the gene promoter ([Table I](#tI-mmr-21-04-1702){ref-type="table"}). Percentage of each CpG site and the mean methylation percentage of the 4 CpGs quantitatively revealed the methylation levels.

### Statistical analysis

The χ^2^ test was used to detect gender differences among TD, NTD and HC groups. Pearson\'s correlation analysis was concurrently used to examine the correlations among methylation levels among the 4 CpG sites, average level of the 4 CpG sites and severity of SCZ. Differences among the continuous variables including age and education were evaluated by Fisher\'s F test in the GLM. Normality of DNA methylation levels was tested by the Shapiro-Wilk test. Differences of DNA methylation levels among the 3 groups, TD, NTD and HC, for individual CpG sites and the mean of 4 CpGs were detected using GLM. All the analyses were performed using SAS version 9.4 software (SAS Institute, Inc.). The PROC POWER statement in SAS was used to compute power in the present study. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Demographics and clinical characteristics

The demographic factors in the TD, NTD and HC groups are presented in [Table II](#tII-mmr-21-04-1702){ref-type="table"}. No statistical significances were observed in age (P=0.910), sex (P=1.00) and educational levels (P=0.832) among the 3 groups. There were no significant differences between TD and NTD groups in the disease duration and treatment, drug dose quantized using CPZ equivalents or drug types. Additionally, no significant difference was observed between TD and NTD groups in the PANSS total, positive, negative or general scores ([Table III](#tIII-mmr-21-04-1702){ref-type="table"}).

### Normality test

The average DNA methylation levels of the 4 CpG sites followed normal distribution ([Fig. 1](#f1-mmr-21-04-1702){ref-type="fig"}) based on the Shapiro-Wilk test (P\>0.150).

### Correlation analyses

[Table IV](#tIV-mmr-21-04-1702){ref-type="table"} demonstrated that no significant correlations were found among the individual methylation levels of the 4 CpG sites (all P-values \>0.05); however, CpG sites 1 and 4 demonstrated a strong correlation to the mean value of the 4 CpG sites (P\<0.0001). Furthermore, there were no obvious correlations among CpG sites and the severity of SCZ measured by PANSS scores.

### GLM analyses

The linear GLM revealed significant differences with regard to the CpG site 1 and the mean value of the 4 CpG sites (P=0.0001 and P=0.0126, respectively; [Table V](#tV-mmr-21-04-1702){ref-type="table"} and [Fig. 2](#f2-mmr-21-04-1702){ref-type="fig"}), among the 3 groups. Furthermore, the HC group demonstrated higher methylation levels in the CpG site 1 compared with those in TD, NTD and TD + NTD (P=0.0003, P\<0.0001 and P\<0.0001, respectively) and the average of 4 CpG sites (P=0.0176, P=0.0063 and P=0.003, respectively).

Discussion
==========

To the best of our knowledge, this is the first study to quantitatively analyze DNA methylation using pyrosequencing and determine the *IRS1* gene promoter methylation levels of the 4 CpG sites among the TD, NTD and HC groups. GLM analyses revealed lower methylation levels in CpG site 1 and the mean value of the 4 CpG sites of the TD, NTD and TD + NTD groups compared with the control group.

The methylation status of the *IRS1* gene has been found to be associated with SCZ through post-mortem analysis of human brain tissue from 24 patients with SCZ and 24 unaffected controls using the Illumina Infinium HumanMethylation450 Bead Chip ([@b9-mmr-21-04-1702]). Another study using blood samples and Illumina HumanMethylation450 BeadChip reported that *IRS1* was associated with SCZ ([@b28-mmr-21-04-1702]). The present study used pyrosequencing to reveal that the DNA methylation level in SCZ patients (NTD group) was significantly lower compared with healthy controls with regard to the CpG site 1 and average values of the 4 CpG sites in a Chinese sample ([Table V](#tV-mmr-21-04-1702){ref-type="table"}). Furthermore, it was observed that the TD group demonstrated significantly lower DNA methylation levels compared with healthy controls ([Table V](#tV-mmr-21-04-1702){ref-type="table"}).

Studies have previously indicated that insulin may act as a metabolic signal and the *IRS1* gene may influence body weight control and glucose homeostasis ([@b37-mmr-21-04-1702]--[@b39-mmr-21-04-1702]). Furthermore, several studies have also reported associations of *IRS1* polymorphisms with cancer, diabetes, glucose levels and obesity ([@b40-mmr-21-04-1702]--[@b44-mmr-21-04-1702]). Furthermore, insulin/insulin receptor signaling and the insulin-like growth factor (IGF) pathway may have different functions in the central nervous system in brain development, blood glucose regulation, dendritic growth and neuronal apoptosis ([@b37-mmr-21-04-1702],[@b45-mmr-21-04-1702]--[@b48-mmr-21-04-1702]). However, Che *et al* ([@b47-mmr-21-04-1702]) was unable to identify any association between the *IRS1* gene and epilepsy in a Chinese sample but suggested that the genes associated with the insulin signaling pathway may affect the therapeutic response of temporal lobe epilepsy. Previous epidemiologic studies have demonstrated that SCZ and other mental illnesses may increase the risk of developing type 2 diabetes and other metabolic disorders ([@b49-mmr-21-04-1702],[@b50-mmr-21-04-1702]). The co-morbidity of type 2 diabetes and SCZ may partially be due to concurrent biological susceptibility of these two conditions ([@b51-mmr-21-04-1702],[@b52-mmr-21-04-1702]). As an example, the *TCF7L2* gene is associated with both type 2 diabetes and type 2 diabetes with SCZ or the schizoaffective disorder observed in African American patients ([@b50-mmr-21-04-1702]), while the rs7903146 in the *TCF7L2* gene is associated with SCZ ([@b53-mmr-21-04-1702]). Furthermore, insulin-like growth factor II mRNA-binding protein 2 gene (*IGF2BP2*) may be associated with SCZ ([@b54-mmr-21-04-1702]). Additionally, insulin signaling, among other type 2 diabetes-related pathways, could act as a bridge between SCZ and type 2 diabetes ([@b55-mmr-21-04-1702]). However, one previous study could not associate rs1801278 in the *IRS1* gene with SCZ ([@b27-mmr-21-04-1702]). Therefore, the present study provided further evidence of the involvement of *IRS1* gene with regard to the development of SCZ or TD ([Table IV](#tIV-mmr-21-04-1702){ref-type="table"}).

A previous study examined the DNA methylation levels of three CpG sites in the *IRS1* gene with type 2 diabetes using pyrosequencing ([@b26-mmr-21-04-1702]); however, there was no significant difference in the methylation levels of the 3 CpG sites in the *IRS1* gene between the controls and type 2 diabetes patients, which suggested that the DNA methylation levels of the *IRS1* gene did not play a major role in the occurrence of type 2 diabetes ([@b26-mmr-21-04-1702]). The present study revealed that both TD and NTD groups had significantly lower methylation levels in the CpG site 1 and mean values of the 4 CpG sites in the *IRS1* gene compared with healthy controls ([Table V](#tV-mmr-21-04-1702){ref-type="table"}). One primary difference may be that there were 3 CpG sites in the above type 2 diabetes study ([@b26-mmr-21-04-1702]), while there were 4 in the present study; however, it is possible that these CpG sites may be different. Notably, the present study found numerous similarities, which included the fact that DNA methylation levels in the diabetes groups were slightly lower compared with those in the non-diabetes groups, specifically in the CpG sites 1 and 2 in the entire sample. Furthermore, in the above type 2 diabetes study, a similar trend was noted among the groups of men and women, despite the fact that the differences did not reach a 5% significant level ([@b26-mmr-21-04-1702]).

Previous studies have suggested a role of *IRS1* in cognitive impairment and Alzheimer\'s disease ([@b56-mmr-21-04-1702]--[@b59-mmr-21-04-1702]). The present study and the previous reports related to the role of *IRS1* gene methylation in SCZ ([@b9-mmr-21-04-1702],[@b28-mmr-21-04-1702]) may provide adequate evidence to demonstrate that SCZ and Alzheimer\'s disease may share a common network of dysregulation ([@b60-mmr-21-04-1702]). Furthermore, epidemiologic studies have reported a possible association between the insulin resistance of type 2 diabetes mellitus and increased incidence of Alzheimer\'s disease ([@b61-mmr-21-04-1702],[@b62-mmr-21-04-1702]). As a matter of fact, insulin resistance results in a diminished glucose uptake in similar regions of the brain in Alzheimer\'s disease and type 2 diabetes mellitus ([@b58-mmr-21-04-1702],[@b59-mmr-21-04-1702]). Therefore, the *IRS1* gene may have a pleiotropic effect on Alzheimer\'s disease, type 2 diabetes and SCZ.

There are a number of strengths in the current study. First, this is the first study to conduct a quantitative analysis of DNA methylation levels of the *IRS1* gene in SCZ and TD, while previous studies focused on the methylation status in SCZ ([@b9-mmr-21-04-1702],[@b28-mmr-21-04-1702]). Second, the present study applied a GLM to examine the methylation levels of the 4 CpG sites within the *IRS1* gene among TD, NTD and HC groups. Third, the present study tested the normality of the average methylation levels of the 4 CpG sites and observed that the average DNA methylation levels of these sites followed normal distribution. Although correlation analysis was performed, significant correlations among the methylation percentages of the four CpG sites with the severity of SCZ was not observed. However, the present study has certain limitations: First, a peripheral blood sample was used in view of the difficulty in obtaining brain tissues to study the disorders of the central nervous system. Second, the sample size of the three groups in the methylation study was relatively small because the prevalence of TD in general population is typically low. Based on the PROC POWER determined in SAS 9.4, the power level was 63.3% with 30 individuals on comparing overall means in DNA methylation levels for the four CpG sites; however, it was possible to increase the power up to 99.1% while testing the CpG site 1. Third, the present study examined and included a limited number of sites associated with *IRS1* gene methylation (only 4 sites), which highlighted the importance of increasing the number of sites in future investigations. Additionally, there may be variations between medications, which could not have been detected by the present study.

In conclusion, pyrosequencing demonstrated that the DNA methylation levels of the *IRS1* gene in TD and NTD groups were significantly lower compared with the healthy control group. However, the DNA methylation levels in TD did not demonstrate any significant differences compared with those in the NTD group. This is the first study to compare CpG methylation levels of TD and NTD with healthy controls and the findings demonstrated adequate evidence of the possible roles of IRS1-associated DNA methylation in SCZ and TD. In the future, it will be worthy to detect age and gender effects using a large sample and perform the functional study of these 4 CpG sites of the *IRS1* gene to evaluate the role of this gene in the pathogenesis of SCZ and TD.
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![Normality test for the average methylation level for 4 CpG sites.](MMR-21-04-1702-g00){#f1-mmr-21-04-1702}

![F-test based on GLM analysis of the average methylation levels of 4 CpG sites for comparing three groups. HC, healthy controls; NTD, schizophrenia patients without tardive dyskinesia; TD, schizophrenia patients with tardive dyskinesia.](MMR-21-04-1702-g01){#f2-mmr-21-04-1702}

###### 

Primer sequences used in the pyrosequencing analysis.

  Primer type   Primer sequence                       CpG Sites   Position 5′-3′
  ------------- ------------------------------------- ----------- ----------------
  Forward       5′-AGTGGTTATAGAGTTTGATGTTTATTAGT-3′   4           146--174
  Reverse       5′-CCTAAAACCCAAAAACCTAAATCA-3′                    294--271
  Sequencing    5′-GTTTGATGTTTATTAGTTGTAGTA-3′                    158--181

###### 

Descriptive characteristics of patients and controls.

  Variable                         TH group (n=10)   NTH group (n=10)   HC group (n=10)   P-value
  -------------------------------- ----------------- ------------------ ----------------- ---------
  Male/female                      5/5               5/5                5/5               1.000
  Age (years)                        31.6±11.8         33.8±11.0          33.2±11.9       0.910
  Education (years)                10.6±3.2          10.9±2.6           11.4±3.3          0.832
  Duration of disease (years)        11.1±11.1       10.2±9.2           n/a               1.000
  Duration of treatment (months)     25.6±22.1         24.5±26.1        n/a               0.570
  CPZ equivalents (mg)               662.1±431.4       498.4±275.4      n/a               0.474
  Drug type                                                                               0.584
    1 typical antipsychotic        1                 0                  n/a               
    1 atypical antipsychotic       6                 7                  n/a               
    2 atypical antipsychotics      3                 3                  n/a               

TD, schizophrenia patients with tardive dyskinesia; NTD, schizophrenia patients without tardive dyskinesia; HC, healthy controls. P-values are based on χ^2^ test for categorical variable and generalized linear model for continuous variable.

###### 

Clinical parameters of TD and NTD groups.

  Variable                              TH group (n=10)   NTH group (n=10)   P-value
  ------------------------------------- ----------------- ------------------ ----------
  PANSS total score                       74.0±21.6       73.4±9.7           0.633
  PANSS                                                                      
    Positive                            17.0±7.2          18.7±4.6           0.489
    Negative                            23.6±8.5          18.4±6.2           0.184
    General                             33.6±8.6          35.2±7.0           0.458
  Abnormal involuntary movement scale   13.4±5.3          0                  \<0.0001

TD, schizophrenia patients with tardive dyskinesia; NTD, schizophrenia patients without tardive dyskinesia; PANSS, positive and negative syndrome scale. P-values are based on t-test.

###### 

Pearson correlation coefficients among methylation levels and clinical characters.

  Variable       IRS1 Site 1   IRS1 Site 2   IRS1 Site 3   IRS1 Site 4   IRS1 Average                                            PANSST   PANSSP                                                  PANSSN                                                  PANSSG
  -------------- ------------- ------------- ------------- ------------- ------------------------------------------------------- -------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  IRS1 Site 1    1.000         −0.345        0.299         0.285         0.821^[a](#tfn3-mmr-21-04-1702){ref-type="table-fn"}^   −0.323   −0.499                                                  −0.219                                                  −0.121
  IRS1 Site 2                  1.000         −0.055        −0.222        −0.276                                                  −0.092   0.013                                                   0.122                                                   0.037
  IRS1 Site 3                                1.000         0.076         0.310                                                   0.198    0.013                                                   0.266                                                   0.111
  IRS1 Site 4                                              1.000         0.770^[a](#tfn3-mmr-21-04-1702){ref-type="table-fn"}^   0.059    −0.052                                                  −0.051                                                  0.153
  IRS1 Average                                                           1.000                                                   −0.160   −0.366                                                  −0.128                                                  0.008
  PANSST                                                                                                                         1.000    0.521^[b](#tfn4-mmr-21-04-1702){ref-type="table-fn"}^   0.832^[a](#tfn3-mmr-21-04-1702){ref-type="table-fn"}^   0.836^[a](#tfn3-mmr-21-04-1702){ref-type="table-fn"}^
  PANSSP                                                                                                                                  1.000                                                   0.184                                                   0.177
  PANSSN                                                                                                                                                                                          1.000                                                   0.623^[c](#tfn5-mmr-21-04-1702){ref-type="table-fn"}^
  PANSSG                                                                                                                                                                                                                                                  1.000

P\<0.0001

P \<0.05

P\<0.01. IRS1, insulin receptor substrate 1; PANSS, positive and negative syndrome scale; PANSST, the total score; PANSSP, positive score; PANSN, negative score; PANSSG, general psychopathology score.

###### 

General linear model analysis of DNA methylation levels.

  Group              Mean/F/t/P-value            Site 1     Site 2       Site 3       Site 4     Average
  ------------------ --------------------------- ---------- ------------ ------------ ---------- ----------
  TD                 Mean ± standard deviation   84.3±3.8   100.0±0.0    100.0±0.0    86.9±1.3   92.8±1.0
  NTD                                            84.0±3.4     99.7±0.7     99.8±0.7   86.8±2.9   92.6±1.4
  HC                                             90.2±1.4     99.8±0.7   100.0±0.0    87.8±5.6   94.4±1.6
  TD vs. NTD vs HC   F value                     13.14      0.51         0.95         0.14       5.20
                     P-value                     0.0001     0.6052       0.4011       0.8659     0.0126
  TD vs. HC          t value                     −4.22      0.92         0.0          −0.42      −2.53
                     P-value                     0.0003     0.3677       1.0000       0.6758     0.0176
  NTD vs. HC         t value                     −4.59      0.07         −1.20        0.06       −2.97
                     P-value                     \<0.0001   0.9433       0.2403       0.9524     0.0063
  TD + NTD vs. HC    t value                     −5.21      0.56         −0.72        −0.54      −3.26
                     P-value                     \<0.0001   0.5822       0.4762       0.5903     0.0030
  TD vs. NTD         t value                     0.25       0.85         1.17         −0.50      0.36
                     P-value                     0.8072     0.4048       0.2527       0.6237     0.7220

TD, schizophrenia patients with tardive dyskinesia; NTD, schizophrenia patients without tardive dyskinesia; HC, healthy controls. F value is based on GLM for comparing three groups and t value is based on GLM for comparing two groups.
